Early rheumatoid arthritis strategy linked to better 10-year outcomes
A study followed 230 patients with early rheumatoid arthritis who received a strict treat-to-target approach for two years. At ten years, most participants were in remission, had limited joint damage progression, and showed physical function and quality of life near population norms. Those who achieved sustained remission at two years had lower disease activity and better function later.
The ARCTIC trial enrolled 230 people with recently diagnosed rheumatoid arthritis in Norway. Treatment followed a strict target-based plan for two years, and participants were invited back a decade later. Of 218 still living, 179 (82%) took part in the long-term assessment.
At ten years, 82% met disease-activity remission criteria. Joint damage rose only modestly, with a median 2.0-point change on the van der Heijde-modified Sharp score. Physical function and quality of life came close to general-population levels, and survival matched the wider population. Two-year sustained remission was linked to lower later disease activity and better function.
This finding may reassure newly diagnosed RA patients and clinicians that intensive early treatment can lead to durable remission and preserved function. Health systems could see fewer long-term complications and less need for costly care if such strategies are widely applied, though the study's size and single-trial setting limit broad conclusions. Patients and families may benefit from realistic expectations, while payers and clinics may weigh upfront treatment intensity against later savings.